Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 20,682 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Peripheral Blood Clear all

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Natalizumab (Tysabri); Drug
Lead sponsor: Cornerstone Health Care, PA; Other
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Patchogue, New York • High Point, North Carolina • Portland, Oregon

Conditions: Metastatic Colorectal Cancer, Colon Cancer, Colorectal Cancer, Rectal Cancer
Interventions: Placebo, AMG 655, Modified FOLFOX6, Bevacizumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 61
States / cities: Hot Springs, Arkansas • Downey, California • La Jolla, California + 56 more

Conditions: Prostate Cancer, Prostate Adenocarcinoma
Interventions: Blood Collection During Standard of Care Treatment; Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Diabetes, Hypoglycemia
Interventions: 13C-MRS procedure/Acetate infusion, Continuous glucose monitoring; Other · Device
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 40 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Baton Rouge, Louisiana • New Orleans, Louisiana

Conditions: Cystic Fibrosis-related Diabetes
Interventions: Insulin, Continuous glucose monitor (CGM); Drug · Device
Lead sponsor: Jagdeesh Ullal; Other
Eligibility: 18 Years to 80 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Cancer
Interventions: cisplatin, everolimus, paclitaxel, laboratory biomarker analysis; Drug · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 4
States / cities: Chattanooga, Tennessee • Jackson, Tennessee • Knoxville, Tennessee + 1 more

Conditions: Type 2 Diabetes Mellitus (T2DM)
Interventions: MPowerHub, Continuous Glucose Monitor (CGM), Activity Monitor; Device
Lead sponsor: Ann-Marie Rosland; Other
Eligibility: 25 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Grade I Neuroendocrine Carcinoma, Grade II Neuroendocrine Carcinoma, Grade III Neuroendocrine Carcinoma, Metastatic Neuroendocrine Carcinoma, Neuroendocrine Carcinoma, Recurrent Small Cell Lung Carcinoma, Refractory Small Cell Lung Carcinoma, Lung Cancer Stage IV, Large Cell Neuroendocrine Carcinoma, Neuroendocrine Tumors, Small Cell Lung Cancer Metastatic, Small-cell Lung Cancer
Interventions: Nivolumab, Temozolomide; Biological · Drug
Lead sponsor: Dwight Owen; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 2
States / cities: Columbus, Ohio

Conditions: Ulcerative Colitis
Interventions: Adalimumab; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 3
States / cities: Scottsdale, Arizona • Chicago, Illinois • Rochester, Minnesota

Conditions: Heart Transplantation
Interventions: Optison; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Asthma
Interventions: omalizumab, Placebo; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Colorectal Cancer
Interventions: Tivozanib, Bevacizumab, mFOLFOX6; Drug
Lead sponsor: AVEO Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 27
States / cities: Gilbert, Arizona • Hot Springs, Arizona • Tucson, Arizona + 22 more

Conditions: Lymphoma
Interventions: CT-011, Rituximab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Down Syndrome, Chromosome Disorders, Intellectual and Developmental Disabilities
Interventions: Not listed
Lead sponsor: RTI International; Other
Eligibility: Not listed
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 15
States / cities: Orange, California • Aurora, Colorado • Miami, Florida + 12 more

Conditions: Anaphylaxis, Hypotension, Bronchospasm, Angioedema
Interventions: Epinephrine, Omalizumab (Xolair), Placebos; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hematopoietic and Lymphatic System Neoplasm
Interventions: Biospecimen Collection, Dietary Intervention, Questionnaire Administration; Procedure · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Hematologic Disease, Blood Coagulation Disorders
Interventions: Recombinant Factor VIII (Kogenate, BAY 14-2222); Behavioral
Lead sponsor: Bayer; Industry
Eligibility: 14 Years to 29 Years · Male only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 7
States / cities: Duarte, California • Denver, Colorado • Peoria, Illinois + 4 more

Conditions: Breast Cancer
Interventions: denosumab, Surgery; Biological · Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertension
Interventions: Remote Monitoring, Remote Monitoring + Social Support; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 75 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Obstructive Sleep Apnea
Interventions: blood biomarker; Diagnostic Test
Lead sponsor: Beckman Coulter, Inc.; Industry
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Irvine, California • Boston, Massachusetts • Columbia, South Carolina

Conditions: Prostate Cancer
Interventions: bevacizumab, satraplatin; Biological · Drug
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 2
States / cities: Detroit, Michigan

Conditions: Alcohol Use, Alcohol Drinking, Drinking Behavior
Interventions: Smartphone breathalyzer device/app use, BAC estimator app use, Text messaging procedure; Device
Lead sponsor: University of Florida; Other
Eligibility: 21 Years to 25 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Stage IV (Metastatic) Breast Cancer
Interventions: ABI-007, vinorelbine, Trastuzumab, G-CSF; Drug · Biological
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 2
States / cities: Duarte, California • Seattle, Washington

Conditions: Bleeding Reduction
Interventions: Acute Normovolemic Hemodilution; Procedure
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years to 85 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Falls Church, Virginia

Search by objective public record fields.

NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness

Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer

Assess Gamma H2AX Positivity in Circulating Prostate Cancer Cells Before and After Radium 223

Evaluating Glial Acetate Metabolism as a Biomarker of Hypoglycemic Complications in Diabetic Patients

Comparison of Meal-Time Dosing of Insulin in Cystic Fibrosis Related Diabetes

Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer

Helping Adults With Type 2 Diabetes Use Their Health Data for Healthy Diabetes Self-Management

Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer

Open-Label Adalimumab for Ulcerative Colitis Patients

Myocardial Perfusion Echocardiography to Detect Human Heart Transplant Rejection

Effect of Anti-IgE in Non-Allergic Asthma

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma

Collaboration for Down Syndrome Progress (CDP)

A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis

The High Fiber Program to Increase Fiber Intake Among Patients Undergoing Allogeneic Hematopoietic Cell Transplant

Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A

Presurgical Trial of Denosumab in Breast Cancer

Remote Monitoring and Social Support for Hypertension Management

Use of Blood Biomarkers and Biomarker Index to Aid in the Diagnosis of Obstructive Sleep Apnea (OSA)

Satraplatin and Bevacizumab in Treating Patients With Metastatic Prostate Cancer Previously Treated With Docetaxel

Young Adult Naturalistic Alcohol Study (YANAS) Using Smartphone Technology in a Simulated Laboratory Environment

A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer

Biomarker and Thrombogenicity Assessment in Cardiopulmonary Bypass Surgery Utilizing Acute Normovolemic Hemodilution